Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RJV-222
- Development stage
- Preclinical
- Lead developer
- Rejenevie Therapeutics
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
RJV-222 is a **preclinical cell therapy candidate** from **Rejenevie Therapeutics** designed for **aged stromal vascular fraction restoration**. According to the company pipeline, it uses **restorative isolated factors** derived from young healthy cells to restore the function of aging stromal vascular fraction cells, an approach aligned with Rejenevie's broader parabiosis-inspired regenerative medicine platform. The program is being positioned for **all Okyanos treating indications**, but no specific molecular target, dosing form, or administration route has been publicly disclosed.
- Other names
- aged SVF restoration using restorative isolated factors
Beyond the preview
Go deeper on RJV-222.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RJV-222.